Patrick Wingrove
Verified
As seen in:
Thomson Reuters,
G1 Globo,
MSN,
MSN Australia,
MSN Canada,
MSN Ireland,
MSN Malaysia,
MSN Money Canada,
MSN New Zealand,
MSN Singapore,
MSN UK
and
Journalist @Reuters. History lover and jogger.
Articles by Patrick Wingrove
Datos muestran que Wegovy de Novo ayuda a pacientes a perder en torno a 6% de su peso en tres meses Original
Por Patrick Wingrove 14 nov - Los pacientes que siguieron tomando la pastilla diaria Wegovy de Novo Nordisk perdieron una media del 6,2% de su peso corporal en tres meses, según datos del mundo real que se presentarán en la conferencia ObesityWeek de Washington.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 – Patients who stayed on Novo Nordisk’s daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
By Patrick Wingrove LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
A blister pack containing Wegovy (semaglutide) tablets on a line in Novo Nordisk’s facility in Malov, west of Copenhagen, Denmark, July 31, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab LONDON Nov 14 - Patients who stayed on Novo Nordisk's (NOVOb.CO), opens new tab daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
FILE PHOTO: A blister pack containing Wegovy (semaglutide) tablets on a line in Novo Nordisk’s facility in Malov, west of Copenhagen, Denmark, July 31, 2026. REUTERS/Tom Little/File Photo LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
FILE PHOTO: A blister pack containing Wegovy (semaglutide) tablets on a line in Novo Nordisk’s facility in Malov, west of Copenhagen, Denmark, July 31, 2026. REUTERS/Tom Little/File Photo LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
FILE PHOTO: A blister pack containing Wegovy (semaglutide) tablets on a line in Novo Nordisk’s facility in Malov, west of Copenhagen, Denmark, July 31, 2026. REUTERS/Tom Little/File Photo LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington. The pill, launched in January, has helped Novo regain some ground lost to Eli Lilly, and the Danish drugmaker is trying to stay ahead of its US rival in the race for oral obesity treatments.
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
FILE PHOTO: A blister pack containing Wegovy (semaglutide) tablets on a line in Novo Nordisk’s facility in Malov, west of Copenhagen, Denmark, July 31, 2026. REUTERS/Tom Little/File Photo LONDON Nov 14 - Patients who stayed on Novo Nordisk's daily Wegovy pill lost an average of 6.2% of their body weight over three months, according to real-world data due to be presented at the ObesityWeek conference in Washington.
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China
By Andrew Silver and Patrick Wingrove SHANGHAI/LONDON, Nov 12 (Reuters) - Eli Lilly on Thursday became the first drugmaker to win approval in China for a GLP-1 weight-loss pill, giving it an early advantage over Danish rival Novo Nordisk in the world's second-largest pharmaceutical market. Until now, Chinese regulators had approved GLP-1 medications for weight management only in injectable form.
Exclusive-US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
By Patrick Wingrove and Yasmeen Abutaleb By Patrick Wingrove and Yasmeen Abutaleb NEW YORK, Nov 12 (Reuters) - The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, according to six sources familiar with the matter and internal documents.
Report: FDA Shelves Fast-Track Drug Review Program
The US Food and Drug Administration has shelved the fast-track drug review initiative launched during the Trump administration by former Commissioner Marty Makary, according to six sources familiar with the matter and internal documents. Launched in June 2025, the Commissioner's National Priority Voucher program aimed to slash drug review timelines to just one to two months for therapies addressing national priorities, such as urgent unmet health needs.
Show More
loading
Actions
Get in touch with Patrick
Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack